{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"56.3","value":"184.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"81"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Ramucirumab 8 mg/kg IV infusion every 2 weeks. BSC: Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.","id":"OG000","title":"Ramucirumab (IMC-1121B) + BSC"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Participants who received Cycle 7 of Ram and had Cmax results.","reportingStatus":"POSTED","timeFrame":"1 hour following completion of Cycle 7 (14-day cycles) infusion","title":"Cmax of Ramucirumab, Cycle 7","type":"SECONDARY","unitOfMeasure":"µg/mL"}